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Title of special issue : 
 Schizophrenia in the 21st century: new insights and translation into improved therapies 
Guest Editor: Professor Judith Pratt 
This special issue focuses on recent advances in understanding the causes and the 
pathophysiology of schizophrenia, the approaches that are being adopted to translate this 
knowledge into new treatments and the analyses of recent trials with novel non-dopamine based 
treatments. 
Over 100 years have elapsed since schizophrenia was first described and over 50 years since 
chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder.  
With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been 
waves of optimism for improvements in the clinical efficacy of these drugs.  Unfortunately these 
treatments have not fulfilled expectations.  As with chlorpromazine, current medications provide 
relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact 
on the negative symptoms and cognitive deficits.  Moreover, potential drug-induced side effects 
such as motor dysfunction and weight gain are highly undesirable.  Lack of understanding of the 
causes of schizophrenia together with the continued use of dopamine-based preclinical models in 
drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack 
of major breakthroughs for improved treatments.   
The opening articles in this special issue are devoted to reviewing the current status of the causes 
and the neurobiological deficits in schizophrenia.  Harrison emphasises ƚŚĂƚ ? ?ŐĞŶĞƐĨŽƌ
ƐĐŚŝǌŽƉŚƌĞŶŝĂ ?ŚĂǀĞƵŶƋƵĞƐƚŝŽŶĂďůǇďĞĞŶĨŽƵŶĚ ? ? Highlighting results from the 2014 publication 
from the Schizophrenia Working Group of the Psychiatric Genomics Consortium (~37,000 cases and 
~113,000 controls) it is noted that over 100 loci (implicating ~700 genes) are genome-wide 
significant.  Yet, as Harrison points out, each of these single nucleotide polymorphisms (SNPs) has a 
very small effect on disease risk (Odds ratios typically <1.20) and even cumulatively can only partly 
explain genetic predisposition.  Rare variants, gene-gene and gene-environment interactions can 
also help to explain the ~65-80% heritability in schizophrenia.  Harrison underlines that the 
significant advances in the genetic understanding of schizophrenia poses many questions: what is 
the neurobiological role of the gene products?, how do genetic variants converge upon biochemical 
pathways and networks to impact on pathophysiology ? and what are the implications for drug 
discovery ?. It is also becoming apparent that schizophrenia belongs to a family of disorders with 
some interrelationships at the genetic level with bipolar disorder and autism. 
Howes and colleagues provide a timely update of the dopamine and glutamate hypotheses of 
schizophrenia pathophysiology emphasising that there is evidence for DA presynaptic dysfunction 
and glutamatergic abnormalities.  They also argue for an integrated model of these key 
neurotransmitter systems.  Whilst it is currently challenging to mesh the genetic findings in 
schizophrenia with the dopamine hypothesis there is accumulating evidence that many of these risk 
genes are involved in glutamate synapse function.  Hence the neurobiology of some genetic variants 
is at least aligning with some pre-existing neurochemical hypotheses of disease relevance.  
A key aim of schizophrenia research is to define the disorder in biological terms rather than clinical 
presentation.  TŚĞ ?ŽŵŝĐƐ ?Ğra has led to considerable effort in developing biomarkers with the aim 
of providing a clear diagnosis or a response to treatment.  Pickard reviews the range of approaches 
adopted, noting that rather than providing robust biomarkers, the studies have provided insights 
into pathological processes.  New strategies for the extraction of biomarkers from the integration of 
ůĂƌŐĞ ?-ŽŵŝĐƐ ?ĚĂƚĂƐĞƚƐĂƌĞƉƌŽƉŽƐĞĚ.   
  ?dƌĂŶƐůĂƚŝŽŶĂůDĞĚŝĐŝŶĞ ?ŚĂƐďĞĐŽŵĞƚŚĞĂƐƉŝƌĂƚŝŽŶĨŽƌŵĂŶǇĚŝƐĐŝƉůŝŶĞƐŝŶƚŚĞ ? ?ƐƚĐĞŶƚƵƌǇ ?tŚŝůƐt 
this is bearing fruit in cancer research where stratification of patients according to genotype and 
treatment responsiveness is increasingly possible, mental health research remains less tractable. In 
ƚŚŝƐƐƉĞĐŝĂůŝƐƐƵĞ ?ƚƌĂŶƐůĂƚŝŽŶĂů ?ƌĞƐĞĂƌĐŚŝƐŚŝŐŚůŝghted from a range of  ?ƚĞĐŚŶŝĐĂů ?perspectives and 
discussed in the context of drug discovery.  Several articles discuss imaging and electrophysiological 
approaches as translational tools.  Bois and colleagues review structural MRI studies in high risk 
patients, emphasising the utility of neuroanatomical markers for identifying individuals that 
transition to psychosis and thereby providing a rationale for early treatment intervention in the 
appropriate cohort. 
Phillips and Uhlhaas discuss neural oscillations making the important point that brain rhythms are 
largely similar across species.  Hence underlying abnormal rhythmic activity in animal models is 
potentially suitable to understand the mechanisms underlying alterations in neural oscillation in 
schizophrenia that may relate to deficits in perceptual processing, working memory and executive 
function.  These translational electrophysiological paradigms offer good opportunities for drug 
discovery.   Thalamocortical activity contributes to neural oscillations and in this context the 
GABAergic thalamic reticular nucleus (TRN) plays an important role.  Evidence for the TRN being a 
functional hub in thalamocortical network dysfunction potentially leading to a range of 
schizophrenia symptoms is reviewed by Pratt and Morris.   Recent analytical methods of imaging and 
electrophysiological data, characterised at the scale of whole brain networks (using algorithms of 
graph theory) or specific neural subsystem interactions, are providing greater insights into 
compromised functional brain connectivity in schizophrenia.  Dawson and colleagues appraise this 
evidence and stress ƚŚĞƚƌĂŶƐůĂƚŝŽŶĂůǀĂůƵĞŽĨƵƐŝŶŐ ?ĨƵŶĐƚŝŽŶĂůďƌĂŝŶĐŽŶŶĞĐƚŝǀŝƚǇ ?ƉŚĞŶŽƚǇƉĞƐŝŶ
preclinical models for drug discovery.   
At the behavioural level, Foussias and colleagues discuss negative symptoms and Young and Geyer 
review cognitive processes.  Foussias et al note that within the construct of negative symptoms, 
diminished expression and amotivation form the two key subdomains.   Current evidence suggests 
that anhedonia may be intact in schizophrenia challenging traditional views of this being a key 
deficit. Instead other facets of motivation such as reward prediction and reward valuation are 
impaired.  Of course both the negative symptoms and cognitive deficits are inadequately controlled 
by current antipsychotic drugs and so when it comes to drug discovery there are no positive 
controls.  Two salient points made by Young and Geyer which are suggested to facilitate the drug 
discovery process for the identification of pro-cognitive agents are 1) the importance of 
understanding the neural systems underlying a particular cognitive construct and 2) the 
measurement of similar domains in animals and patients.  Foussias and colleagues give similar 
opinions in terms of drug discovery for the negative symptoms.   Given that the complement of 
negative symptom and cognitive deficits may vary between patients, the issue of personalised 
medicines rather than a  ?one-size fits all ? approach will be a challenge for future treatment 
strategies.  
At this point in time, no compound has reached the clinic which has emerged from the 
ĂĨŽƌĞŵĞŶƚŝŽŶĞĚ ?ƚƌĂŶƐůĂƚŝŽŶĂůĂƉƉƌŽĂĐŚĞƐ ?ĨŽƌĚƌƵŐĚŝƐĐŽǀĞƌǇ.  EĞǀĞƌƚŚĞůĞƐƐ ?ĂƌĂŶŐĞŽĨ ?ŶŽŶ-
dopĂŵŝŶĞ ?based compounds have progressed to testing in clinical trials.  Of particular interest are 
compounds such as the mGluR2/3 agonists and glycine transport (GlyT1) inhibitors, which have been 
developed as a result of the glutamate hypothesis of schizophrenia, and, nicotinic acetylcholine 
receptor activators.  Unfortunately these have all met with limited success (reviewed by Rowe et al 
and Dunlop and Brandon).  Dunlop and Brandon consider the potential reasons for the disappointing 
results which include 1) patient recruitment (prior drug history may have had a negative impact on 
responsiveness to the new drug) 2) the lack of consideration of genetic factors in patient selection  
What does the future hold ?  Genetic and  W ?KŵŝĐƐ ? research is likely to lead to the identification of 
pathways and networks that converge and which are potentially  ?drugable ?.  A deeper understanding 
of how risk factors impact at the molecular and cellular level to cause brain circuity dysfunction 
resulting in aberrant brain rhythms, functional connectivity and behaviour will facilitate rational drug 
design.  Ultimately by the next century our descriptions of mental health disorders may have been 
replaced with more mechanistically-ďĂƐĞĚĚŝĂŐŶŽƐĞƐ ? ?EĞƵƌĂůĐŝƌĐƵŝƚĚŝƐŽƌĚĞƌƐ ?potentially 
characterised by a suite of defined  ?ŽŵŝĐ ?ďŝŽŵĂƌŬĞƌƐ.  The development of new treatments to 
correct the neural circuit abnormalities will be dependent on the level of future investment by 
Research Councils, Charities and Industry and the synergistic relationship between them.  Given that 
tens of millions of people worldwide suffer from schizophrenia and mental health disorders, this 
investment seems entirely justifiable. 
 
